Nuon has established a start-up management team to conduct Series 'A' operations in preclinical development, IP management, regulatory submissions and clinical planning. The Company is currently hiring selective additional full time staff and consultants to meet anticipated operational needs of the clinical development plan.
Rodney Pearlman, PhD - CEO
- Previously Co-Founder, CEO and President, Saegis Pharmaceuticals
- Previously SVP R&D, Valentis Gene Therapy
- Previously Director, Pharmaceutical R&D, Genentech, Inc.
- Previously Sr. Scientist, Pharmaceutical Product Development, Eli Lilly and Co.
Helen Jenkins, MA - COO
- Previously SVP, Development Operations, Saegis Pharmaceuticals
- Previously Sr. Director, Product Development, Regulatory Affairs, Valentis
- Previously Director Pharmaceutical R&D, Genentech, Inc.
Michael Selley, PhD - CSO
- Previously Chief of Staff to the Australian Minister for Science and Technology
- Previously academic appointments at the John Cutin School of Medical Research, Australian National University where he carried out research on the molecular basis of cardiovascular diseases
- Nuon Founder, Investor and Shareholder